menu
FR | EN
Digital Healthcare Community
Certified Medical Tourism ProfessionalBest Medical Travel Agency 2015Best use of technology in Medical Travel 2017Certified Temos

News

2 results
New Covid-19 treatments to be made available in France later this year

26/08/2021

New Covid-19 treatments should be widely available in France before the end of the year, the head of the country's Scientific Council has predicted. According to a report in Le Parisien newspaper, Jean-François Delfraissy, an immunologist and president of the Conseil scientifique, which advises the government on medical matters, said monoclonal and polyclonal antibody treatments would be made more widely available in the coming months. Monoclonal antibody treatments are made using Covid-19 survivors’ own antibodies and are designed to fight infection just as the natural immune system would. Former US President Donald Trump received monoclonal antibody drugs when he was hospitalised with Covid-19 in 2020. At the beginning of August, French health authorities authorised the use of monoclonal antibody treatments for immuno-compromised patients who cannot be vaccinated against the virus because of their conditions. The treatments are set to be rolled out for use as required by doctors among the wider population before the end of the year. A number of pharmaceutical companies are in the process of applying for medical authorisation. They would be “effective for high-risk patients, and should reduce the number of hospitalisations”, Le Parisien reported, but would only be available under medical supervision. The drugs are intended for use in patients who are already severely ill with Covid. They do not prevent people developing the illness in the first place. *Image by Klaus Hausmann from Pixabay 

This cost effective, low-dose steroid could be a breakthrough treatment for COVID-19

18/06/2020

Experts in the UK say a cost effective and widely available drug can help save the lives of seriously ill COVID-19 patients. The drug, dexamethasone, a steroid, has been around since the early 1960s, and is usually given in low doses to patients with severe asthma, allergies and painful/swollen joints. It is also used to treat autoimmune conditions, such as systemic lupus erythematosus and rheumatoid arthritis. Dexamethasone’s effect on inflammation and our immune systems is what is believed to make it useful in treating patients with severe COVID-19 infections. The drug is part of the RECOVERY Trial, the largest clinical trial to date aiming to identify treatments that may be beneficial for COVID-19 patients. As part of the trial, researchers studied the effect of dexamethasone in 2,000 patients and compared that to the outcomes in 4,000 patients who did not receive it. Dexamethasone was found to cut the risk of death by a third for patients on ventilators. For those on oxygen, it cut deaths by a fifth. This equates to one life saved for every eight on ventilators and every 20-25 treated with oxygen. One of the biggest benefits of dexamethasone is that it is not cost prohibitive, meaning it could be pivotal for treating COVID-19 in poorer countries. [Related reading: What does it mean for a vaccine if the new coronavirus mutates?]

expand_less